March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Heterogeneous Vancomycin-Intermediate Staphylococci Isolates from Endophthalmitis
Author Affiliations & Notes
  • Paulo J. Bispo
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
    Universidade Federal de São Paulo, São Paulo, Brazil
  • Darlene Miller
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Footnotes
    Commercial Relationships  Paulo J. Bispo, None; Darlene Miller, None
  • Footnotes
    Support  Research to Prevent Blindness, Inc. New York and NIH Core Grant P30-EY14801. P.J.M. Bispo is supported by a grant from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil (3092-10-0).
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6197. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paulo J. Bispo, Darlene Miller; Heterogeneous Vancomycin-Intermediate Staphylococci Isolates from Endophthalmitis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6197.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To investigate the frequency of heterogeneous vancomycin-intermediate (hVI) staphylococci among endophthalmitis isolates.

Methods: : A total of 121 isolates (vancomycin MICs of 0.75 to 2 µg/ml for S. aureus and 0.75 to 3 µg/ml for coagulase-negative staphylococci) collected between 2005-2010 were screened using brain heart infusion agar containing 4 µg/ml of vancomycin for selection of isolates with reduced susceptibility. Isolates selected by agar screening were further evaluated using the modified vancomycin population analysis profile (PAP) - area under curve (AUC) ratio method. PAP-AUC ratio of ≥ 0.9 between isolates and the control heterogeneous vancomycin-intermediate S. aureus - hVISA (Mu3) was used as criteria for confirmation of hVIS staphylococci isolates. Vancomycin and teicoplanin MICs for the parents and subpopulation isolates were determined by reference microbroth dilution. Accessory gene regulator (agr)-typing was also performed for the hVISA isolates.

Results: : In total, 22 out 121 isolates (18.2%) with reduced vancomycin susceptibility were selected by agar screening including 17 S. epidermidis, 2 S. warneri, and 1 isolate of each following species, S. aureus, S. haemolyticus and S. saprophyticus. Vancomycin susceptibility for parents and subpopulation isolates was similar (all susceptible). For teicoplanin, 3 parents and 9 subpopulations of S. epidermidis isolates were intermediate-resistant. Using the PAP-AUC ratio criteria, the overall prevalence of hVI staphylococci isolates was 5% (6 out 121). Those isolates included 5 S. epidermidis (out 17 tested) and 1 methicillin-susceptible S. aureus. The heterogeneous vancomycin-intermediate S. epidermidis (hVISE) isolates were all resistant to ciprofloxacin and belonged to the agr groups II (n=4) and I (n=1).

Conclusions: : Our results show that heterogeneous intermediate-resistance to vancomycin has emerged among S. aureus and S. epidermidis from endophthalmitis. These isolates were also co-resistant to fluoroquinolones. Such a combination of resistance phenotypes could lead to poorer patient outcomes and may constitute an emerging concern for the management of staphylococcal endophthalmitis.

Keywords: endophthalmitis • antibiotics/antifungals/antiparasitics 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.